1. Peter Fields, MD, director of OrthoRegen in Santa Monica, Calif., is offering a stem cell therapy that combines four regenerative orthopedic procedures, according to a Jan. 4 announcement.
2. Richmond-based OrthoVirginia’s Adam Crowl, MD, performed the first spinal fusion in a clinic with the ViBone Moldable cell bone matrix, according to a Jan. 12 news release.
3. Orthobiologics company Bioventus launched its initial public offering Feb. 4.
4. DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, completed construction on its 25,000-square-foot headquarters in Salt Lake City.
5. Patients injected with stem cells derived from their own bone marrow saw improvement in motor functions after spinal cord injuries, a study from New Haven, Conn.-based Yale University found.
6. UC Davis Health in Sacramento, Calif., on March 1 announced the launch of the first FDA-approved human clinical trial using stem cells before birth to treat spina bifida, a defect that occurs when the spine and spinal cord do not form properly.
7. The global regenerative medicine market is projected to reach $39 million by 2030, up from $8.2 million in 2019, according to market research company P&S Intelligence.
More articles on biologics:
Which spine procedures are surgeons migrating to the ASC in 2021?
The next 3 years in spine: What will gain ground on fusion?
5 ways spine surgery is changing: ASCs, endoscopic surgery & more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
